ADmit Therapeutics Competitors and Similar CompaniesClear all

ADmit Therapeutics's competitors and similar companies include Exact Sciences, Trinity Biotech, i2a and LabGenomics.

	ADmit Therapeutics ADmit Therapeutics is a company engaged in the development of an early Alzheimer's disease diagnosis test.	Exact Sciences Exact Sciences is a company that provides cancer screening and diagnostic test products.	Trinity Biotech Trinity Biotech is a company that specializes in the development, manufacture, and marketing of diagnostic test kits.	i2a i2a is a medical diagnostic company specializing in microbiology.	LabGenomics LabGenomics ((주)랩지노믹스) is a healthcare company specializing in molecular diagnostics.
Founding Date	Founding Date 2017	Founding Date 1995	Founding Date 1992	Founding Date 1988	Founding Date 2002
Type	Type Private	Type Public	Type Public	Type Private	Type Public
Tags	Tags Healthcare biotech medical diagnostics medtech	Tags Healthcare biotech medical diagnostics medtech	Tags Healthcare biotech medical diagnostics medtech	Tags Healthcare biotech medical diagnostics medtech	Tags Healthcare biotech medical diagnostics medtech
Locations	Locations L'Hospitalet de Llobregat, ES HQ	Locations Madison, US HQ Paris, FR Cologne, DE Milan, IT Tokyo, JP Baar, CH London, GB see more	Locations Bray, IE HQ Jamestown, US	Locations Montpellier, FR HQ	Locations Seongnam-si, KR HQ
Employees	Employees 13	Employees 6,5003% increase	Employees 380	Employees 1413% increase	Employees 265
Valuation ($)	Valuation ($) N/A	Valuation ($) 12.8 b	Valuation ($) 19.1 m	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $3.2b (FY, 2025)	Revenue (est.) $61.6m (FY, 2024)	Revenue (est.) N/A	Revenue (est.) ₩85.9b (FY, 2024)
Cost of goods	Cost of goods N/A	Cost of goods $984.2m (FY, 2025)	Cost of goods $38.2m (FY, 2024)	Cost of goods N/A	Cost of goods ₩51.3b (FY, 2024)
Gross profit	Gross profit N/A	Gross profit $2.3b (FY, 2025)	Gross profit $23.3m (FY, 2024)	Gross profit N/A	Gross profit ₩43.5b (FY, 2024)
Net income	Net income N/A	Net income ($207.9m) (FY, 2025)	Net income ($31.2m) (FY, 2024)	Net income N/A	Net income (₩23.7b) (FY, 2024)